Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung c
about
Aurora Kinase Inhibitors: Current Status and OutlookRecent advances in the development of Aurora kinases inhibitors in hematological malignanciesDevelopment of cell-cycle checkpoint therapy for solid tumorsAurora kinases: novel therapy targets in cancersDanusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells.A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors.An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor.Multi-kinase inhibitors, AURKs and cancer.Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature.MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope.An update on the developing mitotic inhibitors for the treatment of non-small cell carcinoma.Increased AURKA Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma.A quantitative proteomic response of hepatocellular carcinoma Hep3B cells to danusertib, a pan-Aurora kinase inhibitor.
P2860
Q26770583-9833D076-E73A-494F-91AA-99F181AE5F94Q26775723-9D113470-E07C-4070-A974-349E99E0ED62Q26781187-BBB9877B-0799-4800-A4F6-5A977BB0A235Q33618929-FF38BF12-E32A-4C10-9456-E0BECBC6D571Q36324682-25E9B12D-4B77-49F2-87FF-62990325175CQ37366202-435FAB23-7934-4B0F-B9D6-796F61C15070Q38525073-5C8EC08F-053D-4799-A900-D53B4B5500AFQ38783162-EDBF6E3F-6300-4AA7-AB2D-61858BE27A7BQ38796360-4D3A6F4A-9634-45BC-A6D2-1826FFFD687BQ38813996-C7E5B64F-A059-4C04-B40F-50FEB2E1623CQ39019412-305385F7-0A21-40E1-9DA8-36EA07633EBAQ39393217-3991C8E7-8F50-488B-989F-B6E85CDEA55DQ47553028-C3EBA976-6CB2-4A74-9DA6-32D684BE2117Q52718113-4B933263-FBA6-4FCA-BBF7-A278142A8843Q55312817-31C2F766-8BA5-40DC-8EB3-F10295198419
P2860
Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung c
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Efficacy and safety of biweekl ...... cell and non-small-cell lung c
@en
Efficacy and safety of biweekl ...... cell and non-small-cell lung c
@nl
type
label
Efficacy and safety of biweekl ...... cell and non-small-cell lung c
@en
Efficacy and safety of biweekl ...... cell and non-small-cell lung c
@nl
prefLabel
Efficacy and safety of biweekl ...... cell and non-small-cell lung c
@en
Efficacy and safety of biweekl ...... cell and non-small-cell lung c
@nl
P2093
P2860
P356
P1433
P1476
Efficacy and safety of biweekl ...... i-institutional phase II study
@en
P2093
A Petroccione
J-P Delord
M G Jannuzzo
M J A de Jonge
P Schöffski
P2860
P304
P356
10.1093/ANNONC/MDU566
P577
2014-12-08T00:00:00Z